Amicus Therapeutics Announces Second Quarter 2007 Financial Results

First Page		Document Content
Date: 2014-12-02 16:03:24 Rare diseases Fabry disease Lysosomal storage diseases Renal function Biomarker Enzyme replacement therapy Clinical trial ERT Glycogen storage disease type II Medicine Health Clinical research		Amicus Therapeutics Announces Second Quarter 2007 Financial Results Add to Reading List Source URL: www.fabry.org Download Document from Source Website File Size: 109,34 KB Share Document on Facebook

	Migalastat and Enzyme Replacement Therapy Have Comparable Effects on Renal Function in Fabry Disease: Phase 3 Study Results Nicholls, K1*, Bichet, DG2, Giugliani, R3, Hughes, D4, Schiffmann, R5, Wilcox, W6, Skuban, N7, R DocID: 1tiPw - View Document
	The Journal of Rare Disorders CochraneCorner DocID: 19CDW - View Document
	7 November 2014 Dear Committee Re: Life Saving Drugs Programme Review Fabry Support Group of Australia Submission DocID: W87d - View Document
	Minimum Recommended Schedule of Assessments for MPS I Patients Initial Assessments Every 6 DocID: VV2Y - View Document
	Pancreatic enzyme replacement therapy DocID: V3Jk - View Document